Nurali Shavazi, Marina Ibragimova, Muhiba Ataeva, Maksim Lim
Acute bronchiolitis is the most common cause of hospitalization of children in the first two years of life, which is characterized by manifestations of bronchial obstructive syndrome and respiratory failure. The causative agent of acute bronchiolitis is a virus. Since the main pathogenetic link is the formation of inflammation in the epithelium of the bronchioles by various agents, we conducted treatment using an immunostimulating drug-Broncho-munal. We treated 50 patients aged 6 to 36 months, who were divided into 2 groups. The patients were hospitalized in the Samarkand Branch of the Republican Scientific Center of Emergency Medical Care, in the departments of pediatrics. 25 patients were prescribed Bronxo-munal in an age-related dosage for 10 days. Clinical manifestations of group I, who received the drug Bronxo- munal, were stopped faster by almost 2 times, compared with patients from group II. The use of the drug Bronxo-munal in acute bronchiolitis has shown that it is an effective anti-inflammatory and anti-bronchoconstrictor drug that prevents and reduces the severity of acute bronchiolitis
